Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Imugene.
RELATED STOCKHEAD STORIES
News
ASX Small Cap Lunch Wrap: It’s a rarity to see so much parity; Cooper’s got new copper
News
Short & Caught: Pilbara Minerals is the ASX’s most shorted as lithium prices tumble
Health & Biotech
Check Up: Imugene’s oncolytic virus VAXINIA granted FDA’s Fast Track, but how effective is this novel therapy?
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: Smug ASX ends Tuesday higher, but not much better
News
Top 10 at 10: Special EV loans, M&A, and a big Brazil REE buy
Health & Biotech
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners
Health & Biotech
ScoPo’s (actually Wilkie’s) Powerplays: Yoga = chill. Fact. And ASX health stocks up for second week
News
ASX Small Caps and IPO Weekly Wrap: Up days, down days = flat week; Medtech multiplies its mojo
Health & Biotech
ASX Health Stocks: AVITA flies as high as 24pc after providing a big, bullish guidance
News
Rise and Shine: Everything you need to know before the ASX opens
News
ASX Small Cap Lunch Wrap: Healthcare stocks lead some frankly marvellous ASX gains on Thursday
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: Local markets close lower as RBA bites before Christmas
Health & Biotech
ASX Health Stocks: PYC on the same page with FDA, Cleo’s cancer test peer-reviewed
Health & Biotech
ASX Health Stocks: Island Pharma granted Aussie patent for flavivirus infection drug, ISLA-101
Health & Biotech
